Switch to:
More From Other Websites
Novogen Provides Update On Development Of Cantrixil May 01 2016
Novogen Provides Update on Development of Cantrixil May 01 2016
Cantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) Apr 17 2016
Novogen Receives R&D Tax Incentive Cash Refund Mar 16 2016
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant Feb 19 2016
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed Feb 05 2016
Letter to Shareholders from CEO James Garner Jan 31 2016
Novogen appoints new CEO Dec 09 2015
Novogen Appoints Dr James Garner as Chief Executive Officer Dec 09 2015
NOVOGEN LTD Financials Dec 08 2015
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial Nov 23 2015
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia Nov 11 2015
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina Nov 10 2015
Novogen Applies for Long-Term Options Listing on ASX Sep 30 2015
Novogen Applies for Long-term Options Listing Sep 29 2015
Novogen (NVGN) Conducts Scientific Review of R&D Program Aug 31 2015
Novogen Announces The Outcome Of A Comprehensive Science Review Aug 30 2015
Novogen to review pre-clinical programs Jul 30 2015
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen Jul 29 2015
Novogen to review its pre-clinical trials Jul 29 2015


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK